CO5011087A1 - VITRONECTINE RECEPTORS ANTAGONISTS - Google Patents

VITRONECTINE RECEPTORS ANTAGONISTS

Info

Publication number
CO5011087A1
CO5011087A1 CO98053986A CO98053986A CO5011087A1 CO 5011087 A1 CO5011087 A1 CO 5011087A1 CO 98053986 A CO98053986 A CO 98053986A CO 98053986 A CO98053986 A CO 98053986A CO 5011087 A1 CO5011087 A1 CO 5011087A1
Authority
CO
Colombia
Prior art keywords
vitronectine
alkyl
receptors antagonists
halo
antagonists
Prior art date
Application number
CO98053986A
Other languages
Spanish (es)
Inventor
William E Bondinell
William H Miller
Dirk Heerding
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of CO5011087A1 publication Critical patent/CO5011087A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • C07D233/48—Nitrogen atoms not forming part of a nitro radical with acyclic hydrocarbon or substituted acyclic hydrocarbon radicals, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/12—Nitrogen atoms not forming part of a nitro radical
    • C07D239/14—Nitrogen atoms not forming part of a nitro radical with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02—Seven-membered rings
    • C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D313/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D313/14—[b,f]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

Un compuesto según la fórmula (I):en la cual:A es CH2 u O;R1 es H, halo o alquilo C1-6 ;R2 es H, alquilo C1-6 o CH2 NR"R";X es O o CH2 ;Y esG es NR", S u O;R´ es H, alquilo C1-6 , O-alquilo C1-6 , S-alquilo C1-6 ,NR"R" o halo;cada R" es independientemente H o alquilo C1-6 ; ys es 0 1 ó 2;o una sal farmacéuticamente aceptable del mismo.A compound according to formula (I): in which: A is CH2 or O; R1 is H, halo or C1-6 alkyl; R2 is H, C1-6 alkyl or CH2 NR "R"; X is O or CH2 ; Y esG is NR ", S or O; R 'is H, C1-6 alkyl, O-C1-6 alkyl, S-C1-6 alkyl, NR" R "or halo; each R" is independently H or alkyl C1-6; and s is 0 1 or 2; or a pharmaceutically acceptable salt thereof.

CO98053986A 1997-09-19 1998-09-18 VITRONECTINE RECEPTORS ANTAGONISTS CO5011087A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5934297P 1997-09-19 1997-09-19
US6343897P 1997-10-29 1997-10-29

Publications (1)

Publication Number Publication Date
CO5011087A1 true CO5011087A1 (en) 2001-02-28

Family

ID=26738652

Family Applications (1)

Application Number Title Priority Date Filing Date
CO98053986A CO5011087A1 (en) 1997-09-19 1998-09-18 VITRONECTINE RECEPTORS ANTAGONISTS

Country Status (26)

Country Link
EP (1) EP1025090A4 (en)
JP (1) JP2001517658A (en)
KR (1) KR20010024141A (en)
CN (1) CN1278250A (en)
AP (1) AP2000001766A0 (en)
AR (1) AR015446A1 (en)
AU (1) AU738433B2 (en)
BG (1) BG104314A (en)
BR (1) BR9812340A (en)
CA (1) CA2303487A1 (en)
CO (1) CO5011087A1 (en)
DZ (1) DZ2609A1 (en)
EA (1) EA200000336A1 (en)
HU (1) HUP0003641A3 (en)
ID (1) ID24162A (en)
IL (1) IL135028A0 (en)
MA (1) MA26547A1 (en)
NO (1) NO20001407L (en)
NZ (1) NZ503389A (en)
OA (1) OA11341A (en)
PE (1) PE122699A1 (en)
PL (1) PL339381A1 (en)
SK (1) SK4082000A3 (en)
TR (1) TR200000721T2 (en)
TW (1) TW513303B (en)
WO (1) WO1999015508A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO4920232A1 (en) * 1997-01-08 2000-05-29 Smithkline Beecham Corp DIBENZO [A, D] CYCLLOHEPTANE ACETIC ACIDS WITH VITRONECTIN RECEPTOR ANTAGONIST ACTIVITY
EP1150965A4 (en) 1999-02-03 2002-05-15 Merck & Co Inc Benzazepine derivatives as alpha-v integrin receptor antagonists
DE19936780A1 (en) * 1999-08-09 2001-02-15 Basf Ag New integrin receptor antagonists
EG24179A (en) * 1999-09-07 2008-09-28 Smithkline Beecham Corp Vitronectin receptor antagonists
US6881736B1 (en) 1999-09-07 2005-04-19 Smithkline Beecham Corporation Vitronectin receptor antagonists
US6514964B1 (en) 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
FR2806082B1 (en) * 2000-03-07 2002-05-17 Adir NOVEL BICYCLIC ANTAGONIST VITRONECTIN RECEPTOR COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
JP2004503540A (en) 2000-06-15 2004-02-05 ファルマシア・コーポレーション Dihydrostilbene alkanoic acid derivatives useful as integrin antagonists
ES2259047T3 (en) * 2000-10-24 2006-09-16 MERCK & CO., INC. INTEGRINE RECEIVER ANTAGONIST OF DIBENZOXAZEPINA.
AU2002316855B2 (en) 2001-04-24 2008-03-13 Merck Patent Gmbh Combination therapy using anti-angiogenic agents and TNFalpha
GB0215867D0 (en) * 2002-07-09 2002-08-14 Glaxosmithkline Spa Novel method and compounds
US20040224986A1 (en) 2002-08-16 2004-11-11 Bart De Corte Piperidinyl targeting compounds that selectively bind integrins
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
CA2637387A1 (en) 2006-01-18 2007-07-26 Simon Goodman Specific therapy using integrin ligands for treating cancer
WO2008087025A2 (en) 2007-01-18 2008-07-24 Merck Patent Gmbh Specific therapy and medicament using integrin ligands for treating cancer
US20120130146A1 (en) 2009-05-25 2012-05-24 Merck Patent Gmbh Continuous administration of cilengitide in cancer treatments
RU2016146826A (en) 2014-05-30 2018-07-04 Пфайзер Инк. CARBONITRIL DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH443281A (en) * 1964-02-18 1967-09-15 Hoffmann La Roche Process for the preparation of dibenzocycloheptatriene compounds
US3335148A (en) * 1966-02-17 1967-08-08 Lilly Co Eli 9(3-pyridyl)derivative of fluorene, 9-fluorenol, xanthene, 9-xanthenol and the corresponding nonphytotoxic acid addition salts thereof
US5698551A (en) * 1995-04-07 1997-12-16 Novo Nordisk A/S Heterocyclic compounds
SI0910563T1 (en) * 1995-06-29 2003-10-31 Smithkline Beecham Corporation Integrin receptor antagonists
US5659033A (en) * 1995-09-13 1997-08-19 Neurogen Corporation N-aminoalkylfluorenecarboxamides; a new class of dopamine receptor subtype specific ligands
EP0946180A4 (en) * 1996-10-07 2003-07-23 Smithkline Beecham Corp Method for stimulating bone formation
CO4920232A1 (en) * 1997-01-08 2000-05-29 Smithkline Beecham Corp DIBENZO [A, D] CYCLLOHEPTANE ACETIC ACIDS WITH VITRONECTIN RECEPTOR ANTAGONIST ACTIVITY

Also Published As

Publication number Publication date
NZ503389A (en) 2002-03-28
DZ2609A1 (en) 2003-03-01
AR015446A1 (en) 2001-05-02
EA200000336A1 (en) 2000-10-30
EP1025090A4 (en) 2000-11-08
EP1025090A1 (en) 2000-08-09
JP2001517658A (en) 2001-10-09
NO20001407D0 (en) 2000-03-17
MA26547A1 (en) 2004-12-20
OA11341A (en) 2003-12-10
AP2000001766A0 (en) 1998-09-18
KR20010024141A (en) 2001-03-26
TW513303B (en) 2002-12-11
AU738433B2 (en) 2001-09-20
ID24162A (en) 2000-07-13
NO20001407L (en) 2000-03-17
CN1278250A (en) 2000-12-27
BR9812340A (en) 2001-12-18
SK4082000A3 (en) 2000-09-12
IL135028A0 (en) 2001-05-20
AU9397298A (en) 1999-04-12
PL339381A1 (en) 2000-12-18
TR200000721T2 (en) 2000-11-21
BG104314A (en) 2001-01-31
PE122699A1 (en) 2000-02-12
CA2303487A1 (en) 1999-04-01
HUP0003641A3 (en) 2002-10-28
HUP0003641A2 (en) 2001-03-28
WO1999015508A1 (en) 1999-04-01

Similar Documents

Publication Publication Date Title
CO5011087A1 (en) VITRONECTINE RECEPTORS ANTAGONISTS
EA199700117A1 (en) TRICYCLIC BENZE-GOLDEN ANTAGONISTS VAZOPRESSIN, METHOD FOR THEIR RECOVERY, PHARMACEUTICAL COMPOSITION AND METHOD OF TREATMENT OF MAMMALS USING Tricyclic Benzene
ES2123287T3 (en) DERIVATIVES 3-BENZOIL BENZOFURANICOS AS ANTAGONISTS OF THE THYROID HORMONE.
MY132529A (en) Paroxetine hydrochloride anhydrate
ATE107499T1 (en) HAIR STRENGTHENING AGENT.
EA199700111A1 (en) TRICYCLIC BENZE-ZEPINE ANTAGONISTS VAZOPRESSINA
HK1044333A1 (en) Chemokine receptor antagonists and methods of use therefor
ATE309249T1 (en) CHEMOKINE RECEPTOR ANTAGONISTS AND USES
NO20012194D0 (en) CRF receptor antagonists and associated methods
HK1038925B (en) Crf receptor antagonists and methods relating thereto
CO5090837A1 (en) DERIVATIVES OF 1,3,4-OXADIAZOLONA
PL341539A1 (en) Heterocyclic toxins of topoisomerases
BR9807085A (en) Il-8 receptor antagonists
EA200400692A1 (en) ANTAGONISTS OF THE CHEMOKINE RECEPTOR AND METHODS OF THEIR APPLICATION
ATE284871T1 (en) BICYCLIC VASOPRESSIN AGONISTS
ITMI941809A0 (en) PROCEDURE FOR THE PRODUCTION OF BRUSHES AS WELL AS MACHINE FOR THE PRODUCTION OF BRUSHES FOR CARRYING OUT THE PROCEDURE
MX9603199A (en) Endotheline receptors antagonists.
ATE234098T1 (en) 4-AMINOPYRROLE (3,2-D) PYRIMIDINES AS ANTAGONISTS OF THE NEUROPEPTIDE Y RECEPTOR
NO302816B1 (en) 15-deoxy pergualin analogs and their use, as well as intermediates for their preparation
ES2061749T3 (en) HETERO-CYCLE COMPOUNDS AND ANTI-ULCER AGENTS.
IT1284097B1 (en) SUSPENSION PROCESS FOR THE PREPARATION OF ETHYLENE ELASTOMERIC COPOLYMERS
ZW6789A1 (en) &-adrenergic receptor antagonists
MA23130A1 (en) PROCESS FOR THE PREPARATION OF A BENZYLIMIDAZOPYRIDINE DERIVATIVE AS AN ANTAGONIST OF ANGIOTENSIN II RECEPTORS.
ECSP982672A (en) VITRONECTIN III RECEPTOR ANTAGONISTS
ATE114310T1 (en) ALPHA ADRENEGIC RECEPTOR ANTAGONISTS.